The NPPA says it has also revised the price cap of 15 planned formulations under Drugs (Prices Control) Order, 2013 (NLEM 2022).
The NPPA has set the price of one tablet of diabetes drug Gliclazide ER and Metformin Hydrochloride Tablets at Rs 10.03
The national drug pricing regulator NPPA said on Friday it has firm selling prices of 23 formulations, including the drugs to treat diabetes and high blood pressure. The National Pharmaceutical Pricing Authority (NPPA) has set prices under the Drugs (Price Control) Order, 2013 based on the decision of the 113th meeting of the Authority on May 26, 2023.
As per the notice, the NPPA has set the price of one tablet of diabetes drug Gliclazide ER and Metformin Hydrochloride Tablets at Rs 10.03.
Similarly, the retail price of one tablet of Telmisartan, Chlortalidone & Cilnidipine Tablets is Rs 13.17. The retail price of one tablet containing painkillers Trypsin, Bromelain, Rutoside Trihydrate and Diclofenac Sodium Tablets is set at Rs 20.51.
The NPPA said it also reviewed the price cap of 15 planned formulations under Drugs (Prices Control) Order, 2013 (NLEM 2022).
It also has a fixed ceiling price of two planned formulations.
In addition, it has a fixed and revised cap price of one planned formulation, the notice said.
The NPPA is mandated to set/review the prices of controlled bulk drugs and formulations and to enforce prices and availability of the drugs in the country. It also monitors the prices of deregulated drugs to keep them at reasonable levels.
The regulatory agency implements and enforces the provisions of the Drugs (Prices Control) Order.
It is also tasked with recovering amounts overcharged by manufacturers for controlled medicines from consumers.
(This story has not been edited by News18 staff and was published from a syndicated news agency feed – PTI)
